Europe Cell & Gene Therapy Bioanalytical Testing Services Market Size & Outlook
- HC Outsourcing
- Clinical & Non-Clinical Outsourcing Services
- Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
- Clinical & Non-Clinical Outsourcing Services
Europe Cell Gene Therapy Bioanalytical Testing Services Market, 2018-2030 (US$M)
Global Market
Related Markets
Ask a question about the cell & gene therapy bioanalytical testing services market
Europe cell & gene therapy bioanalytical testing services market highlights
- The Europe cell & gene therapy bioanalytical testing services market generated a revenue of USD 90.1 million in 2023.
- The market is expected to grow at a CAGR of 7% from 2024 to 2030.
- In terms of segment, bioavailability & bioequivalence studies was the largest revenue generating test type in 2023.
- Bioavailability & Bioequivalence Studies is the most lucrative test type segment registering the fastest growth during the forecast period.
- Country-wise, Germany is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 90.1 million |
| Market revenue in 2030 | USD 144.3 million |
| Growth rate | 7% (CAGR from 2023 to 2030) |
| Largest segment | Bioavailability & bioequivalence studies |
| Fastest growing segment | Bioavailability & Bioequivalence Studies |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type |
| Key market players worldwide | IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC |
Other key industry trends
- In terms of revenue, Europe region accounted for 17.8% of the global cell & gene therapy bioanalytical testing services market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 277.6 million by 2030.
Similar to North America, Europe has established regulatory frameworks to help in the development and marketing of cell and gene therapies. Regulatory agencies, such as the European Medicines Agency (EMA), offer possibilities for fast approval and limited marketing authorization for novel therapies.
This favorable regulatory environment promotes investment and innovation in the field of cell & gene therapies. The EMA, the medical regulatory body for the European Union, has been a global leader in evaluating advanced therapy medicinal products, a class of novel biological products that include gene therapy.
In 2009, the EMA approved a tissue-engineering product, 1 year ahead of the U.S. to approve its first ATMP. It also approved the world's first gene therapy in 2012. Advanced therapy medicinal products are divided into three main categories: somatic Cell Therapy Medicinal Products (sCTMPs), Gene Therapy Medicinal Products (GTMPs), and Tissue-Engineered Products (TEPs).
No credit card required*
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell & Gene Therapy Bioanalytical Testing Services Market Scope
Cell Gene Therapy Bioanalytical Testing Services Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Charles River Laboratories International Inc | View profile | 21,400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | www.criver.com |
| Labcorp Holdings Inc | View profile | 67,000 | 358 South Main Street, Burlington, NC, United States, 27215 | www.labcorp.com |
| IQVIA Holdings Inc | View profile | 87,000 | 2400 Ellis Road, Durham, NC, United States, 27703 | www.iqvia.com |
| Intertek Group PLC | View profile | 44,000 | 33 Cavendish Square, London, United Kingdom, W1G 0PS | www.intertek.com |
| Syneos Health | View profile | 1001-5000 | Morrisville, North Carolina, United States, North America | www.syneoshealth.com/ |
| Pharmaron Beijing Co Ltd Ordinary Shares - Class H | View profile | 20,295 | No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Wanchai, Hong Kong, Hong Kong | www.pharmaron.com |
Europe Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell & Gene Therapy Bioanalytical Testing Services Market Outlook will help companies and investors design strategic landscapes.
Bioavailability & Bioequivalence Studies was the largest segment with a revenue share of 35.29% in 2023.
Horizon Databook has segmented the Europe cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
Similar to North America, Europe has established regulatory frameworks to help in the development and marketing of cell and gene therapies. Regulatory agencies, such as the European Medicines Agency (EMA), offer possibilities for fast approval and limited marketing authorization for novel therapies.
This favorable regulatory environment promotes investment and innovation in the field of cell & gene therapies. The EMA, the medical regulatory body for the European Union, has been a global leader in evaluating advanced therapy medicinal products, a class of novel biological products that include gene therapy.
In 2009, the EMA approved a tissue-engineering product, 1 year ahead of the U.S. to approve its first ATMP. It also approved the world's first gene therapy in 2012. Advanced therapy medicinal products are divided into three main categories: somatic Cell Therapy Medicinal Products (sCTMPs), Gene Therapy Medicinal Products (GTMPs), and Tissue-Engineered Products (TEPs).
- Europe Cell & Gene Therapy Bioanalytical Testing Services Market Indication Outlook (Revenue, USD million , 2018-2030)
- Infectious Diseases
- Rare Diseases
- Oncology
- Others
- Neurological disorders
- Europe Cell & Gene Therapy Bioanalytical Testing Services Market Test Type Outlook (Revenue, USD million , 2018-2030)
- Other test type
- Pharmacodynamics
- Bioavailability & Bioequivalence Studies
- Pharmacokinetics
- Europe Cell & Gene Therapy Bioanalytical Testing Services Market Product Outlook (Revenue, USD million , 2018-2030)
- Cell Therapy
- Gene-Modified Cell Therapy
- Gene Therapy
- Europe Cell & Gene Therapy Bioanalytical Testing Services Market Stage of Development Outlook (Revenue, USD million , 2018-2030)
- Clinical
- Non-Clinical
Reasons to subscribe to Cell & Gene Therapy Bioanalytical Testing Services Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cell & Gene Therapy Bioanalytical Testing Services Market Outlook databook
- Our clientele includes a mix of Cell & Gene Therapy Bioanalytical Testing Services Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Europe Cell & Gene Therapy Bioanalytical Testing Services Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Europe cell & gene therapy bioanalytical testing services market statistics, by indication, 2018-2030 (US$M)
